Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022006601 - HUMAN RECOMBINANT ACE2-FC MUTANTS THAT DECOUPLE ANTI-SARS-COV-2 ACTIVITY FROM CARDIOVASCULAR EFFECTS

Publication Number WO/2022/006601
Publication Date 06.01.2022
International Application No. PCT/US2021/070820
International Filing Date 02.07.2021
IPC
C12N 15/62 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • NORTHWESTERN UNIVERSITY [US]/[US]
Inventors
  • JIN, Jing
  • LIU, Pan
Agents
  • MCBRIDE, M., Scott
Priority Data
63/047,74102.07.2020US
63/065,45813.08.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HUMAN RECOMBINANT ACE2-FC MUTANTS THAT DECOUPLE ANTI-SARS-COV-2 ACTIVITY FROM CARDIOVASCULAR EFFECTS
(FR) MUTANTS D'ACE2-FC RECOMBINÉS HUMAINS DÉCOUPLANT L'ACTIVITÉ ANTI-SARS-COV-2 DES EFFETS CARDIOVASCULAIRES
Abstract
(EN) Disclosed are compounds, compositions, and methods for treating and/or preventing infection by viruses that utilize the angiotensin converting enzyme 2 (ACE2) as a cellular receptor such as sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Particularly disclosed are recombinant ACE2-Fc fusion proteins and ACE2 variants that exhibit anti-SARS-CoV-2 binding activity and decouple anti-SARS-CoV-2 activity from side effects such as cardiovascular effects, where the fusion proteins and variants exhibit reduced ACE2 enzymatic activity.
(FR) Sont divulgués des composés, des compositions et des méthodes pour traiter et/ou prévenir une infection par des virus qui utilisent l'enzyme de conversion de l'angiotensine 2 (ACE2) en tant que récepteur cellulaire tel qu'un coronavirus responsable du syndrome respiratoire aigu sévère 2 (SARS-CoV-2). Sont en particulier divulgués des protéines de fusion ACE2-Fc recombinées et des variants d'ACE2 qui présentent une activité de liaison anti-SARS-CoV-2 et découplent l'activité anti-SARS-CoV-2 des effets secondaires tels que les effets cardiovasculaires, les protéines de fusion et les variants présentant une activité enzymatique d'ACE2 réduite.
Latest bibliographic data on file with the International Bureau